Literature DB >> 35412137

Coronavirus Entry Inhibitors.

Qiaoshuai Lan1, Shuai Xia1, Lu Lu2.   

Abstract

Coronaviruses (CoVs) are enveloped RNA viruses that widely exist in the environment. Several CoVs possess a strong ability to infect humans, termed as human coronavirus (HCoVs). Among seven known HCoVs, SARS-CoV-2, SARS-CoV, and MERS-CoV belong to highly pathogenic HCoVs, which can cause severe clinical symptoms and even death. Especially, the current COVID-19 pandemic severely threatens human survival and health, which emphasizes the importance of developing effective CoV vaccines and anti-CoV agents to protect humans from HCoV infections. Coronavirus entry inhibitors can block various processes in viral entry, such as receptor binding, proteolytic activation of spike protein, or virus-cell membrane fusion. Coronavirus entry inhibitors, alone or in combination with other drugs, play important roles in the treatment of coronavirus diseases. Thus, we summarize and discuss the development of coronavirus entry inhibitors in this chapter.
© 2022. Springer Nature Singapore Pte Ltd.

Entities:  

Keywords:  Coronavirus; Entry inhibitor; Membrane fusion; Proteolytic activation; Receptor binding

Mesh:

Year:  2022        PMID: 35412137     DOI: 10.1007/978-981-16-8702-0_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  106 in total

Review 1.  Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19.

Authors:  Çağla Begüm Apaydın; Gözde Çınar; Gökçe Cihan-Üstündağ
Journal:  Curr Drug Targets       Date:  2021       Impact factor: 3.465

2.  SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2.

Authors:  Fatima Amanat; Mahima Thapa; Tinting Lei; Shaza M Sayed Ahmed; Daniel C Adelsberg; Juan Manuel Carreño; Shirin Strohmeier; Aaron J Schmitz; Sarah Zafar; Julian Q Zhou; Willemijn Rijnink; Hala Alshammary; Nicholas Borcherding; Ana Gonzalez Reiche; Komal Srivastava; Emilia Mia Sordillo; Harm van Bakel; Jackson S Turner; Goran Bajic; Viviana Simon; Ali H Ellebedy; Florian Krammer
Journal:  Cell       Date:  2021-06-08       Impact factor: 66.850

3.  The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study).

Authors:  Giancarlo Ceccarelli; Francesco Alessandri; Alessandra Oliva; Cristian Borrazzo; Serena Dell'Isola; Anna Maria Ialungo; Elena Rastrelli; Massimiliano Pelli; Giammarco Raponi; Ombretta Turriziani; Franco Ruberto; Monica Rocco; Francesco Pugliese; Alessandro Russo; Gabriella d'Ettorre; Mario Venditti
Journal:  J Med Virol       Date:  2021-03-26       Impact factor: 2.327

4.  REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.

Authors:  Alina Baum; Dharani Ajithdoss; Richard Copin; Anbo Zhou; Kathryn Lanza; Nicole Negron; Min Ni; Yi Wei; Kusha Mohammadi; Bret Musser; Gurinder S Atwal; Adelekan Oyejide; Yenny Goez-Gazi; John Dutton; Elizabeth Clemmons; Hilary M Staples; Carmen Bartley; Benjamin Klaffke; Kendra Alfson; Michal Gazi; Olga Gonzalez; Edward Dick; Ricardo Carrion; Laurent Pessaint; Maciel Porto; Anthony Cook; Renita Brown; Vaneesha Ali; Jack Greenhouse; Tammy Taylor; Hanne Andersen; Mark G Lewis; Neil Stahl; Andrew J Murphy; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-10-09       Impact factor: 47.728

5.  De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.

Authors:  Longxing Cao; Inna Goreshnik; Brian Coventry; James Brett Case; Lauren Miller; Lisa Kozodoy; Rita E Chen; Lauren Carter; Alexandra C Walls; Young-Jun Park; Eva-Maria Strauch; Lance Stewart; Michael S Diamond; David Veesler; David Baker
Journal:  Science       Date:  2020-09-09       Impact factor: 47.728

6.  An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.

Authors:  Kui K Chan; Timothy J C Tan; Krishna K Narayanan; Erik Procko
Journal:  Sci Adv       Date:  2021-02-17       Impact factor: 14.136

7.  Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.

Authors:  Cathrine Axfors; Andreas M Schmitt; Perrine Janiaud; Janneke Van't Hooft; Sherief Abd-Elsalam; Ehab F Abdo; Benjamin S Abella; Javed Akram; Ravi K Amaravadi; Derek C Angus; Yaseen M Arabi; Shehnoor Azhar; Lindsey R Baden; Arthur W Baker; Leila Belkhir; Thomas Benfield; Marvin A H Berrevoets; Cheng-Pin Chen; Tsung-Chia Chen; Shu-Hsing Cheng; Chien-Yu Cheng; Wei-Sheng Chung; Yehuda Z Cohen; Lisa N Cowan; Olav Dalgard; Fernando F de Almeida E Val; Marcus V G de Lacerda; Gisely C de Melo; Lennie Derde; Vincent Dubee; Anissa Elfakir; Anthony C Gordon; Carmen M Hernandez-Cardenas; Thomas Hills; Andy I M Hoepelman; Yi-Wen Huang; Bruno Igau; Ronghua Jin; Felipe Jurado-Camacho; Khalid S Khan; Peter G Kremsner; Benno Kreuels; Cheng-Yu Kuo; Thuy Le; Yi-Chun Lin; Wu-Pu Lin; Tse-Hung Lin; Magnus Nakrem Lyngbakken; Colin McArthur; Bryan J McVerry; Patricia Meza-Meneses; Wuelton M Monteiro; Susan C Morpeth; Ahmad Mourad; Mark J Mulligan; Srinivas Murthy; Susanna Naggie; Shanti Narayanasamy; Alistair Nichol; Lewis A Novack; Sean M O'Brien; Nwora Lance Okeke; Léna Perez; Rogelio Perez-Padilla; Laurent Perrin; Arantxa Remigio-Luna; Norma E Rivera-Martinez; Frank W Rockhold; Sebastian Rodriguez-Llamazares; Robert Rolfe; Rossana Rosa; Helge Røsjø; Vanderson S Sampaio; Todd B Seto; Muhammad Shehzad; Shaimaa Soliman; Jason E Stout; Ireri Thirion-Romero; Andrea B Troxel; Ting-Yu Tseng; Nicholas A Turner; Robert J Ulrich; Stephen R Walsh; Steve A Webb; Jesper M Weehuizen; Maria Velinova; Hon-Lai Wong; Rebekah Wrenn; Fernando G Zampieri; Wu Zhong; David Moher; Steven N Goodman; John P A Ioannidis; Lars G Hemkens
Journal:  Nat Commun       Date:  2021-04-15       Impact factor: 14.919

8.  Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease.

Authors:  James Brett Case; Rita E Chen; Longxing Cao; Baoling Ying; Emma S Winkler; Max Johnson; Inna Goreshnik; Minh N Pham; Swathi Shrihari; Natasha M Kafai; Adam L Bailey; Xuping Xie; Pei-Yong Shi; Rashmi Ravichandran; Lauren Carter; Lance Stewart; David Baker; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2021-06-24       Impact factor: 21.023

9.  Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  J Ryan Bariola; Erin K McCreary; Richard J Wadas; Kevin E Kip; Oscar C Marroquin; Tami Minnier; Stephen Koscumb; Kevin Collins; Mark Schmidhofer; Judith A Shovel; Mary Kay Wisniewski; Colleen Sullivan; Donald M Yealy; David A Nace; David T Huang; Ghady Haidar; Tina Khadem; Kelsey Linstrum; Christopher W Seymour; Stephanie K Montgomery; Derek C Angus; Graham M Snyder
Journal:  Open Forum Infect Dis       Date:  2021-05-17       Impact factor: 3.835

Review 10.  Structural insights into SARS-CoV-2 proteins.

Authors:  Rimanshee Arya; Shweta Kumari; Bharati Pandey; Hiral Mistry; Subhash C Bihani; Amit Das; Vishal Prashar; Gagan D Gupta; Lata Panicker; Mukesh Kumar
Journal:  J Mol Biol       Date:  2020-11-24       Impact factor: 5.469

View more
  1 in total

Review 1.  Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.

Authors:  Qiaoshuai Lan; Lijue Wang; Fanke Jiao; Lu Lu; Shuai Xia; Shibo Jiang
Journal:  J Med Virol       Date:  2022-09-13       Impact factor: 20.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.